|
gptkbp:instanceOf
|
gptkb:drug
ergoline derivative
|
|
gptkbp:approvalYear
|
1978
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N04BC01
|
|
gptkbp:brand
|
Cycloset
Parlodel
|
|
gptkbp:CASNumber
|
25614-03-3
|
|
gptkbp:category
|
antiparkinsonian agent
dopaminergic agent
antidiabetic agent
prolactin inhibitor
|
|
gptkbp:chemicalFormula
|
C32H40BrN5O5
|
|
gptkbp:contraindication
|
uncontrolled hypertension
hypersensitivity to ergot alkaloids
|
|
gptkbp:discoveredBy
|
gptkb:Sandoz
|
|
gptkbp:eliminationHalfLife
|
12-14 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bromocriptine
|
|
gptkbp:isomerOf
|
bromocriptine mesylate
|
|
gptkbp:KEGGID
|
D00206
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine agonist
|
|
gptkbp:MedlinePlusID
|
a682079
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
654.6 g/mol
|
|
gptkbp:origin
|
derived from ergot fungus
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
90-96%
|
|
gptkbp:PubChem_CID
|
31101
CHEMBL1377
DB01200
|
|
gptkbp:riskFactor
|
may cause fibrosis
may cause hallucinations
may cause impulse control disorders
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
headache
hypotension
|
|
gptkbp:synonym
|
2-bromo-α-ergocryptine
|
|
gptkbp:UNII
|
QZU4H1IW0N
|
|
gptkbp:usedFor
|
gptkb:hyperprolactinemia
gptkb:Parkinson's_disease
gptkb:type_2_diabetes_mellitus
acromegaly
|
|
gptkbp:bfsParent
|
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|